Established in 2004, Ningbo Menovo Pharmaceutical Co., Ltd. (hereinafter referred to as"Menovo", stock code: 603538) is a comprehensive pharmaceutical enterprise which integrates R & D, pilot plant test, production, and sales of pharmaceutical intermediates, APIs and finished medicines, headquartered in Ningbo High-tech District, owning 5 wholly-funded subsidiaries, 3 strategically shareholding companies, 1 Sino-Europe jointly-funded pharmaceutical company, 2provincial-class medicine institutes (technological centers) and 1 formulation R & D center in Anhui Province, Zhejiang Province, etc., and setting up offices in India, USA and Europe. Menovo is one of the top 100 manufacturing enterprisesand top 100 competitive enterprises in Ningbo City, one of the top 10 enterprises in the pharmaceutical industry in Ningbo City, and has total assets of over RMB 1.5 billion yuan and more than 1,900 employees currently. On Apr. 7, 2017, Menovo was listed on the main board of the Shanghai Stock Exchange and became the first listed company specializing in the pharmaceutical industry in Ningbo City.
The company's production base has accepted and passed the domestic GMP authentication, the USA FDA audit, the EU official GMP authentication and the Japanese PMDA authentication. It is one of domestic enterprises that exported most varieties of characteristic APIs to Europe. The products involve multiple therapeutic fields including the cardiovascular, central nervous, respiratory system, antitumor, anti-infection, digestive system, geriatric diseases and antiviral systems and the leading products are APIs and intermediates of valsartan, rosuvastatin, atorvastatin, clopidogrel, perindopril and esomeprazole. 6 products including pregabalinhave,have been identified as leading or advanced products in China. By the end of 2017, Menovo had owned 87 invention patents, and over 30 items were being examined or disposed of.
By the implementation of the development strategy of "connotative growth and extension expansion", in accordance with the requirements of "modern enterprises and international standards", adhering to the development idea of "controlling upstreamindustry, developing downstreamindustry, vigorously promoting drug terminal consumption industry, strongly expanding the field of new biopharmaceuticals", and adopting the way of high-end generic drugs of Sino-US and Sino-Europe, Menovo is to upgrade the integrated industrial chain of "pharmaceutical intermediates, APIs and formulations". The company will draw on the management experience of advanced enterprises in the world, vigorously implement the strategy of talent innovation, technology innovation and management innovation, and make efforts to make Menovo into a domestic first-class, internationally known and highly competitive international pharmaceutical enterprise.
Since its establishment in 2004, all members of the company have successfully passed authentication and inspection of official institutions at home and abroad. Among them, the main products of Zhejiang Menovo and Anhui Menovo passed the official GMP audit authentication of the European Medicines Agency in 2008, 2011, 2014 and 2017, and MenovoTiankang oral solid preparations (workshop) passed the Chinese new version of GMP authentication. Liaoyuan Pharmaceutical also passed the US FDA audit and the Japanese PMDA authentication. Menovo is one of domestic enterprises that exported most varieties of characteristic APIs to Europe and America.